Carmel Capital Management’s Pfizer PFE Stock Holding History

Carmel Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,750	Closed	-$211K	–	33
2023 Q2	$211K	Hold	5,750	–	–	0.11%	32
2023 Q1	$235K	Hold	5,750	–	–	0.13%	32
2022 Q4	$295K	Hold	5,750	–	–	0.18%	32
2022 Q3	$252K	Hold	5,750	–	–	0.16%	34
2022 Q2	$301K	Sell	5,750 -300	-5%	-$15.3K	0.19%	33
2022 Q1	$313K	Hold	6,050	–	–	0.16%	34
2021 Q4	$357K	Buy	+6,050	New	+$300K	0.18%	33

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carmel Capital Management's PFE Position: Q3 2023 in Review

Carmel Capital Management sold out of Pfizer (PFE) in Q3 2023, closing a stake of 5,750 shares — an estimated $211K sold.

Carmel Capital Management first reported a position in PFE in Q4 2021 and held it in 7 quarters. The position peaked at $357K in Q4 2021. 2,925 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

Carmel Capital Management reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
Carmel Capital Management sold 5,750 Pfizer shares in Q3 2023, an estimated $211K.
Carmel Capital Management first reported a position in Pfizer in Q4 2021 and held it in 7 quarters.
Carmel Capital Management's Pfizer position peaked at $357K in Q4 2021.
2,925 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Carmel Capital Management's 13F filing for Q3 2023, filed 12 Oct 2023.